AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21387350 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration of 1 mg metolazone
Number of subjects: 0
Study 21387350 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration of 2 mg metolazone
Number of subjects: 0
Study 21387350 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of 1 mg metolazone
Number of subjects: 0
Study 19409085 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group sessions (n = 127) over 4 months
Number of subjects: 250
Study 19409085 — intervention group
Group type: COMPARATOR
Intervention: Single, non-interactive health education session (n = 123)
Number of subjects: 250
Study 19409085 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group sessions (n = 127)
Number of subjects: 250
Study 19409085 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular self-weighers in the intervention group
Number of subjects: 250
Study 19409085 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 250
Study 19409085 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 250
Study 17851785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure vessel-sealing system
Number of subjects: 124
Study 17851785 — intervention group
Group type: COMPARATOR
Intervention: Conventional hand tie method
Number of subjects: 124
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine‐sulfadoxine (PS)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ plus chlorpheniramine (CQCP)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: PS combined with CQ or AQ (COM)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: PS combined with probenecid (PPS)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine (HF)
Number of subjects: 1048
Study 15490757 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 1048
Study 15490757 — intervention group
Group type: COMPARATOR
Intervention: CQCP
Number of subjects: 1048
Study 15490757 — intervention group
Group type: EXPERIMENTAL
Intervention: Gametocyte carriage
Number of subjects: 1048
Study 12002908 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg, twice daily)
Number of subjects: 84
Study 12002908 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 9054280 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (11 mg for 1 week and then ≤ 22 mg for 3 weeks)
Number of subjects: 64
Study 9054280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7697691 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg plus hydrochlorothiazide 12.5 mg once daily
Number of subjects: 93
Study 7697691 — intervention group
Group type: COMPARATOR
Intervention: Benazepril alone (10 mg once daily)
Number of subjects: 93
Study 3316297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 12
Study 3316297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 12
Study 3316297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study 31493013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral water bath plus physical therapy
Number of subjects: 92
Study 31493013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud application procedures plus physical therapy
Number of subjects: 92
Study 31493013 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 92
Study 31493013 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 92
Study 31493013 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS questionnaire
Number of subjects: 92
Study 31343477 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-bubble detection test (M group)
Number of subjects: 300
Study 31343477 — intervention group
Group type: COMPARATOR
Intervention: Smooth saline injection test (S group)
Number of subjects: 300
Study 28025582 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 785
Study 28025582 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 785
Study 24621064 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation (500 mg/day)
Number of subjects: 48
Study 24621064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23909930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early multidisciplinary assessment by a physiotherapist, a psychotherapist, and an occupational therapist within a week.
Number of subjects: 33
Study 23909930 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 33
Study 21936492 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar disinfection (SODIS) of drinking water
Number of subjects: 1089
Study 21936492 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1089
Study 19808924 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 20
Study 19808924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy, exenatide, and daclizumab
Number of subjects: 20
Study 16702822 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20 mg/day)
Number of subjects: 440
Study 16702822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate (5 mg/day)
Number of subjects: 440
Study 16702822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 12890955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol alone (20 mg loading dose, continuous infusion of 1 mg/ml tramadol at 8 ml/h)
Number of subjects: 51
Study 12890955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (20 ml bupivacaine 0.125% loading dose, continuous infusion of 8 ml/h)
Number of subjects: 51
Study 12890955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tramadol and bupivacaine (20 mg tramadol loading dose, 20 ml bupivacaine 0.125% loading dose, continuous infusion of 1 mg/ml tramadol in 20 ml bupivacaine 0.125% at 8 ml/h)
Number of subjects: 51
Study 10655253 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (40-160 mg/d)
Number of subjects: 146
Study 10655253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate (10-20 mg 3 times per day)
Number of subjects: 146
Study 8737763 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release oxybutynin tablet (10 mg) after a high fat breakfast
Number of subjects: 23
Study 8737763 — intervention group
Group type: COMPARATOR
Intervention: Controlled release oxybutynin tablet (10 mg) in fasting subjects
Number of subjects: 23
Study 1329480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 1000
Study 1329480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 1329480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril, enalapril, captopril, digoxin
Number of subjects: 1000
Study 3858304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum
Number of subjects: 0
Study 3858304 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study 3858304 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (no gum)
Number of subjects: 0
Study 30264745 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 2.5% gel with a low glycemic load diet
Number of subjects: 84
Study 30264745 — intervention group
Group type: COMPARATOR
Intervention: Topical benzoyl peroxide 2.5% gel with a normal diet
Number of subjects: 84
Study 30558645 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (T-T group)
Number of subjects: 125
Study 30558645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P-T group)
Number of subjects: 125
Study 27046654 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory organizational-level intervention focusing on the core task at work
Number of subjects: 3039
Study 27046654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3039
Study 25041917 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) angioplasty
Number of subjects: 40
Study 25041917 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon angioplasty
Number of subjects: 40
Study 22421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence QSNYL (Group A)
Number of subjects: 75
Study 22421647 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peel (Group B)
Number of subjects: 75
Study 22421647 — intervention group
Group type: COMPARATOR
Intervention: High-fluence QSNYL (Group C)
Number of subjects: 75
Study 20632453 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN‐alpha) therapy
Number of subjects: 474
Study 18760148 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100mg of levodopa plus 25mg of carbidopa)
Number of subjects: 18
Study 18760148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16398595 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg Chinese red yeast rice (CRYR)
Number of subjects: 11
Study 16398595 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lovastatin
Number of subjects: 11
Study 12053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 mg)
Number of subjects: 154
Study 12053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 154
Study 12053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil (16 mg)
Number of subjects: 154
Study 12053590 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 154
Study 12053590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 10607712 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 microg granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 10
Study 10607712 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 10607712 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF in vitro
Number of subjects: 10
Study 10607712 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 10
Study 8609227 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg per min) for 3 hours (EPI-3)
Number of subjects: 17
Study 8609227 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg per min) for 24 hours (EPI-24)
Number of subjects: 17
Study 8609227 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline before epinephrine infusion)
Number of subjects: 17
Study 1360807 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (5, 10, 20, 40 mg p.o.)
Number of subjects: 12
Study 1360807 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine butylbromide (HBB) (40 mg, s.c.)
Number of subjects: 12
Study 6140340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 22
Study 31035309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabigerol (CBG) 120 mg/kg
Number of subjects: 66
Study 31035309 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin only
Number of subjects: 66
Study 31035309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Cannabigerol (CBG)
Number of subjects: 66
Study 29045584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 18
Study 29045584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26743812 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature controlled laminar airflow (TLA) delivered by the Airsonett™ device for one year
Number of subjects: 222
Study 26743812 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 222
Study 26743812 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature controlled laminar airflow (TLA)
Number of subjects: 222
Study 24408989 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute carnosine supplementation (20 mg/kg body weight)
Number of subjects: 235
Study 24408989 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 235
Study 24408989 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute carnosine supplementation
Number of subjects: 235
Study 24408989 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive athletes
Number of subjects: 235
Study 22293891 — intervention group
Group type: COMPARATOR
Intervention: Levulan-PDT and placebo (Eucerin as vehicle cream)
Number of subjects: 34
Study 22293891 — intervention group
Group type: EXPERIMENTAL
Intervention: Levulan-PDT and imiquimod
Number of subjects: 34
Study 20871168 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone plus birid triple viable
Number of subjects: 120
Study 20871168 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone
Number of subjects: 120
Study 17600039 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 3208
Study 17600039 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 3208
Study 15647778 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (n=24)
Number of subjects: 70
Study 15647778 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (n=24)
Number of subjects: 70
Study 15647778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (n=22)
Number of subjects: 70
Study 11422770 — intervention group
Group type: EXPERIMENTAL
Intervention: One unit of blood matched for one HLA-DR antigen (N = 49)
Number of subjects: 144
Study 11422770 — intervention group
Group type: EXPERIMENTAL
Intervention: One unit of mismatched blood (N = 48)
Number of subjects: 144
Study 11422770 — intervention group
Group type: COMPARATOR
Intervention: Untransfused (N = 47)
Number of subjects: 144
Study 9423499 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Number of subjects: 206
Study 9423499 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 206
Study 8485789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol (100 mg diluted in 10 ml normal saline)
Number of subjects: 20
Study 8485789 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (4 mg)
Number of subjects: 20
Study 8485789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 20
Study 8485789 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 20
Study 2712272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 10 mg, 20 minutes prior to electroconvulsive therapy
Number of subjects: 5
Study 2712272 — intervention group
Group type: COMPARATOR
Intervention: Control (no nifedipine)
Number of subjects: 5
Study 2712272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5
Study 4594580 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 30
Study 4594580 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study 30414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections into epicardial fat pads
Number of subjects: 60
Study 30414841 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections into epicardial fat pads
Number of subjects: 60
Study 30414841 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections
Number of subjects: 60
Study 30414841 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 60
Study 28168677 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Peer Advocate (FPA) intervention
Number of subjects: 0
Study 28168677 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study 26117698 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study 26117698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23583246 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus lineage-specified stem cells
Number of subjects: 0
Study 23583246 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 21817198 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg once daily (plus placebo)
Number of subjects: 1011
Study 21817198 — intervention group
Group type: COMPARATOR
Intervention: NVP IR 200 mg twice daily (plus placebo)
Number of subjects: 1011
Study 21817198 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP XR
Number of subjects: 1011
Study 21817198 — intervention group
Group type: COMPARATOR
Intervention: NVP IR
Number of subjects: 1011
Study 19565730 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application using Chinese medicine (Zhinanxing, Sanleng, Ezhu) at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6)
Number of subjects: 61
Study 19565730 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Tianqi Tongjing Capsules
Number of subjects: 61
Study 16442386 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 1186
Study 15624744 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg subcutaneous efalizumab weekly for 12 weeks
Number of subjects: 339
Study 15624744 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with weekly SC efalizumab after Week 12
Number of subjects: 339
Study 15624744 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended efalizumab therapy
Number of subjects: 339
Study 11502231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (59.7% carbohydrates, 25.7% fat, 7.8% monounsaturates)
Number of subjects: 32
Study 11502231 — intervention group
Group type: COMPARATOR
Intervention: Oil-rich diet (37.8% carbohydrates, 44.4% fat, 19.3% monounsaturates)
Number of subjects: 32
Study 9266866 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg)
Number of subjects: 16
Study 9266866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8298070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardizem SR
Number of subjects: 24
Study 8298070 — intervention group
Group type: COMPARATOR
Intervention: Bi-Tildiem
Number of subjects: 24
Study 3552840 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) treatment
Number of subjects: 23
Study 3552840 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study 29792492 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Step program
Number of subjects: 7419
Study 27725248 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg fludrocortisone, a MR agonist
Number of subjects: 80
Study 27725248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25435850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 (standard half hour i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Number of subjects: 106
Study 25435850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 250 mg/m2 (prolonged 6-hours i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Number of subjects: 106
Study 23031217 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO₂ at 2.4 ATA
Number of subjects: 50
Study 23031217 — intervention group
Group type: COMPARATOR
Intervention: Sham compression (room air at 1.3 ATA)
Number of subjects: 50
Study 19346279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-450 mg)
Number of subjects: 71
Study 19346279 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 71
Study 18160532 — intervention group
Group type: EXPERIMENTAL
Intervention: KB2115
Number of subjects: 0
Study 16636155 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition processes and structure
Number of subjects: 0
Study 16636155 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning and planning products
Number of subjects: 0
Study 16636155 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation actions
Number of subjects: 0
Study 16636155 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities and collaborations
Number of subjects: 0
Study 16636155 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated intermediate outcomes
Number of subjects: 0
Study 16636155 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected asthma related health outcomes
Number of subjects: 0
Study 12794540 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based (CB) training
Number of subjects: 289
Study 12794540 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led (IL) training
Number of subjects: 289
Study 10642013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including patient education, physician reminders, and audit-with-feedback.
Number of subjects: 4481
Study 10642013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 4481
Study 10642013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group compared to control group.
Number of subjects: 4481
Study 10642013 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to physician mammography referral in the intervention group.
Number of subjects: 4481
Study 9863127 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinmaitong Capsule (XMTC)
Number of subjects: 25
Study 9863127 — intervention group
Group type: COMPARATOR
Intervention: Composite Danshen Tablet (CDT)
Number of subjects: 25
Study 8518020 — intervention group
Group type: EXPERIMENTAL
Intervention: SMF (prednimustine + methotrexate + 5-fluorouracil)
Number of subjects: 153
Study 8518020 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide + methotrexate + 5-fluorouracil)
Number of subjects: 153